Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Core Insights - Alector, Inc. is advancing its clinical pipeline for neurodegenerative diseases, with key trials expected to report results in late 2025 [1][2][5] - The company has extended its cash runway into the second half of 2027, with a total of $354.6 million in cash, cash equivalents, and investments as of March 31, 2025 [1][12] Clinical Developments - The pivotal INFRONT-3 Phase 3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation is on track to report topline data in Q4 2025 [2][5] - Enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease has been completed ahead of schedule [4][6] - Alector is pursuing its Alector Brain Carrier programs, which include an anti-amyloid beta antibody and GCase enzyme replacement therapy, both targeting validated genetic pathways [2][7] Financial Performance - Collaboration revenue for Q1 2025 was $3.7 million, a decrease from $15.9 million in Q1 2024, primarily due to the completion of obligations related to previous programs [9] - Total R&D expenses for Q1 2025 were $33.6 million, down from $45.2 million in the same quarter of 2024, reflecting cost management efforts [10] - The net loss for Q1 2025 was $40.5 million, or $0.41 per share, compared to a net loss of $36.1 million, or $0.38 per share, in Q1 2024 [11][20] Corporate Updates - Giacomo Salvadore, M.D., has been appointed as Chief Medical Officer, bringing over 15 years of experience in neurology-focused clinical development [8] - Alector continues to leverage its proprietary blood-brain barrier technology platform, Alector Brain Carrier, to enhance therapeutic delivery to the brain [7][15]